Tesamorelin 10mg

Each lot of this material is analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC) and is released at ≥99% purity. Molecular identity is confirmed by mass spectrometry (MS) against the expected molecular weight of the peptide.

• Identity: Confirmed by mass spectrometry (MS).
• Purity: ≥99% by RP-HPLC.
• CAS: 218949-48-5.
• Form: Lyophilized powder.
• Lot-specific values (net peptide content, exact mass, retention profile) are reported on the Certificate of Analysis (COA) accompanying each lot.

These analyses are analytical characterizations of identity and purity only and do not constitute any representation regarding suitability for any in-vivo or human application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by Zynix Biolab.

Tesamorelin (CAS 218949-48-5) is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH 1-44). As reported in the literature, it comprises the 44-amino-acid sequence of human GHRH bearing a trans-3-hexenoic acid modification, a structural feature that has been described as conferring resistance to enzymatic cleavage and an extended plasma half-life relative to native GHRH.

In published third-party research, the compound has been studied as an agonist of the growth hormone-releasing hormone receptor (GHRHR), a G protein-coupled receptor expressed on anterior pituitary somatotrophs. The receptor-signaling mechanism (Gs/adenylyl cyclase/cAMP/PKA-CREB) and the resulting modulation of growth hormone gene transcription have been characterized in the scientific literature.

As a matter of third-party regulatory history, the compound has been approved in other regulatory contexts under the brand name Egrifta (and the later F8 formulation, EGRIFTA WR) for reduction of excess visceral abdominal adipose tissue in adults with HIV-associated lipodystrophy. It has been the subject of multiple registered clinical investigations indexed on ClinicalTrials.gov (for example, NCT02196831). These references describe research and regulatory activity conducted by third parties and do not represent testing or approval of this product by Zynix Biolab. This material is supplied for research use only and is not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published third-party literature, Tesamorelin has been investigated in laboratory and research settings including:

• Characterization of binding and agonist activity at the growth hormone-releasing hormone receptor (GHRHR) in receptor-signaling assays.
• In-vitro examination of GHRHR-mediated second-messenger pathways (cAMP/PKA-CREB signaling) and growth hormone gene-expression endpoints.
• Comparative analytical studies of GHRH-analog peptide stability and resistance to enzymatic degradation.
• Reference and standard use in HPLC/MS method development for GHRH-analog identity and purity workflows.

These application areas are provided for scientific context only, reflect work reported by third parties, and are not for human use, diagnostic use, or therapeutic use.

For laboratory bench handling and storage:

• Storage: Store the lyophilized powder at -20°C, protected from light and moisture. Long-term storage of the lyophilized form preserves stability.
• Reconstitution: For laboratory preparation, reconstitute with bacteriostatic or sterile water by adding the diluent slowly against the vial wall and allowing the peptide to dissolve without agitation.
• Reconstituted material: Keep refrigerated (2-8°C) and aliquot to minimize freeze-thaw cycles.
• PPE: Handle with appropriate personal protective equipment (gloves, lab coat, eye protection) under standard laboratory safety practices.

The information above describes laboratory handling of a research material and is not a dosing or administration instruction. For research use only — not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. DOI: 10.1056/NEJMoa072375
• Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. PMID: 22495074.
• ClinicalTrials.gov. Tesamorelin Effects on Liver Fat and Histology in HIV. Identifier: NCT02196831.

These references are provided for scientific context only and are not claims by Zynix Biolab.